Davide Busato

Aviano, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal adenocarcinoma.

PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal adenocarcinoma.

Journal: Nanomedicine (London, England)

Published: May 25, 2026

Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer.

Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer.

Journal: Medicina (Kaunas, Lithuania)

Published: March 12, 2025

Idarubicin-loaded chitosan nanobubbles to improve survival and decrease drug side effects in hepatocellular carcinoma.

Idarubicin-loaded chitosan nanobubbles to improve survival and decrease drug side effects in hepatocellular carcinoma.

Journal: Nanomedicine (London, England)

Published: January 15, 2025

The anti-glypican 1 AT101 antibody as targeting agent to effectively deliver chitosan nanobubbles to glioblastoma cells.

The anti-glypican 1 AT101 antibody as targeting agent to effectively deliver chitosan nanobubbles to glioblastoma cells.

Journal: Nanomedicine (London, England)

Published: December 02, 2024

A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma.

A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma.

Journal: Journal of translational medicine

Published: October 06, 2023

Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models.

Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models.

Journal: Frontiers in immunology

Published: April 04, 2023

The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma.

The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma.

Journal: International journal of molecular sciences

Published: August 03, 2022

Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies.

Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies.

Journal: International journal of molecular sciences

Published: August 03, 2022

A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma Patients.

A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma Patients.

Journal: International journal of molecular sciences

Published: December 23, 2020

Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies.

Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies.

Journal: Cancers

Published: May 22, 2020

New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma.

New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma.

Journal: Cancers

Published: July 01, 2019

Novel immunotherapeutic approaches for hepatocellular carcinoma treatment.

Novel immunotherapeutic approaches for hepatocellular carcinoma treatment.

Journal: Expert review of clinical pharmacology

Published: March 26, 2019

Showing 1-12 of 12

Last Updated: 09/26/2026